GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » UCB SA (XBRU:UCB) » Definitions » Price-to-Free-Cash-Flow

UCB (XBRU:UCB) Price-to-Free-Cash-Flow : 54.72 (As of Apr. 27, 2024)


View and export this data going back to 1988. Start your Free Trial

What is UCB Price-to-Free-Cash-Flow?

As of today (2024-04-27), UCB's share price is €124.55. UCB's Free Cash Flow per Share for the trailing twelve months (TTM) ended in Dec. 2023 was €2.28. Hence, UCB's Price-to-Free-Cash-Flow Ratio for today is 54.72.

The historical rank and industry rank for UCB's Price-to-Free-Cash-Flow or its related term are showing as below:

XBRU:UCB' s Price-to-Free-Cash-Flow Range Over the Past 10 Years
Min: 8.02   Med: 19.46   Max: 79.95
Current: 54.83

During the past 13 years, UCB's highest Price-to-Free-Cash-Flow Ratio was 79.95. The lowest was 8.02. And the median was 19.46.

XBRU:UCB's Price-to-Free-Cash-Flow is ranked worse than
65.42% of 214 companies
in the Biotechnology industry
Industry Median: 30.76 vs XBRU:UCB: 54.83

UCB's Free Cash Flow per Share for the six months ended in Dec. 2023 was €1.81. Its Free Cash Flow per Share for the trailing twelve months (TTM) ended in was €2.28.

During the past 12 months, the average Free Cash Flow per Share Growth Rate of UCB was -40.60% per year. During the past 3 years, the average Free Cash Flow per Share Growth Rate was -15.40% per year. During the past 5 years, the average Free Cash Flow per Share Growth Rate was -18.70% per year.

During the past 13 years, UCB's highest 3-Year average Free Cash Flow per Share Growth Rate was 96.80% per year. The lowest was -20.90% per year. And the median was -6.15% per year.


UCB Price-to-Free-Cash-Flow Historical Data

The historical data trend for UCB's Price-to-Free-Cash-Flow can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

UCB Price-to-Free-Cash-Flow Chart

UCB Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Price-to-Free-Cash-Flow
Get a 7-Day Free Trial Premium Member Only Premium Member Only 11.63 22.42 18.38 19.16 34.61

UCB Semi-Annual Data
Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Price-to-Free-Cash-Flow Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 18.38 - 19.16 - 34.61

Competitive Comparison of UCB's Price-to-Free-Cash-Flow

For the Biotechnology subindustry, UCB's Price-to-Free-Cash-Flow, along with its competitors' market caps and Price-to-Free-Cash-Flow data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


UCB's Price-to-Free-Cash-Flow Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, UCB's Price-to-Free-Cash-Flow distribution charts can be found below:

* The bar in red indicates where UCB's Price-to-Free-Cash-Flow falls into.



UCB Price-to-Free-Cash-Flow Calculation

UCB's Price-to-Free-Cash-Flow ratio for today is calculated as

Price-to-Free-Cash-Flow Ratio=Share Price/ Free Cash Flow per Share (TTM)
=124.55/2.276
=54.72

UCB's Share Price of today is €124.55.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. UCB's Free Cash Flow per Share for the trailing twelve months (TTM) ended in Dec. 2023 was €2.28.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

Price-to-Free-Cash-Flow Ratio=Market Cap/Free Cash Flow

UCB  (XBRU:UCB) Price-to-Free-Cash-Flow Explanation

Free Cash Flow is considered more important than earnings by value investors. The reason is because, in principle, only the net cash that can be taken from the business belongs to shareholders. This Free Cash Flow can be used to grow the business, reduce debt or return to shareholders in dividends or share buybacks.

In a DCF Calculation Free Cash Flow is used to determine the intrinsic value of companies.


Be Aware

In real business, Free Cash Flow can be affected by the change in accounts receivable, accounts payable, management's decision on expansion, etc. Therefore, investors should look at the Free Cash Flow over the longer term. Long-term average of Free Cash Flow is a more reliable indicator for real free cash flow.


UCB Price-to-Free-Cash-Flow Related Terms

Thank you for viewing the detailed overview of UCB's Price-to-Free-Cash-Flow provided by GuruFocus.com. Please click on the following links to see related term pages.


UCB (XBRU:UCB) Business Description

Industry
Address
Allee de la Recherche, 60, Brussels, BEL, B-1070
UCB is a Belgium-based biopharma firm focused on the development of novel therapies for the treatment of central nervous system and immunologic diseases. Historically, revenue was derived from allergy medicine Zyrtec and epilepsy drug Keppra, which have both lost patent protection. The firm's key products are Cimzia (immunology), Vimpat (epilepsy), Neupro (Parkinson's disease and restless leg syndrome), Briviact (epilepsy), Bimzelx (psoriasis), Evenity (osteoporosis), Nayzilam (cluster seizures), and Fintepla (Dravet Syndrome and Lennox-Gastaut Syndrome).

UCB (XBRU:UCB) Headlines

No Headlines